Blocking tumor necrosis factor-alpha inhibits folic acid-induced acute renal failure

Bing Wan1, Li Hao, Yuhua Qiu

  • 1Joint Immunology Laboratory of Institute of Health Sciences, Chinese Academy of Sciences and Medical College of Shanghai, Jiao Tong University, Shanghai, China.

Insights

Folic acid (FA) causes acute kidney injury by increasing tumor necrosis factor-alpha (TNF-alpha), which triggers cell death. Blocking TNF-alpha with an antibody protects against FA-induced kidney damage.

Area of Science:

  • Nephrology
  • Toxicology
  • Immunology

Background:

  • Folic acid (FA) administration is a model for studying acute renal failure (ARF).
  • The precise molecular mechanisms underlying FA-induced ARF are not fully elucidated.

Purpose of the Study:

  • To investigate the role of tumor necrosis factor-alpha (TNF-alpha) in FA-induced acute renal failure.
  • To explore the potential therapeutic effect of anti-TNF-alpha antibody in FA-mediated kidney injury.

Main Methods:

  • Systemic administration of folic acid to CD-1 mice to induce acute renal failure.
  • Measurement of blood urea nitrogen (BUN), histological analysis (necrosis, apoptosis), and assessment of TNF-alpha and BclxL expression.
  • In vivo and ex vivo experiments using neutralizing anti-TNF-alpha antibody treatment.

Main Results:

  • FA-treated mice exhibited elevated BUN, renal tubular necrosis, and apoptosis.
  • Increased TNF-alpha and decreased BclxL expression were observed in kidneys of FA-treated mice.
  • Anti-TNF-alpha antibody treatment ameliorated FA-induced ARF by restoring BclxL and inhibiting apoptosis.

Conclusions:

  • TNF-alpha is a key inflammatory mediator in folic acid-induced acute renal failure.
  • Neutralizing anti-TNF-alpha antibody shows promise as a therapeutic strategy for preventing and treating FA-mediated ARF.

Related Concept Videos

Renal Failure: Dose Adjustments01:11

Renal Failure: Dose Adjustments

In patients with renal impairment, drugs undergo significant changes in their pharmacokinetics, which require dosage adjustments to ensure safe and effective therapy.
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Acute Kidney Injury IV: Diagnostic Studies and Prevention01:30

Acute Kidney Injury IV: Diagnostic Studies and Prevention

Accurate diagnosis and effective prevention are critical in managing Acute Kidney Injury (AKI), which is linked to high mortality rates ranging from 10% to 80%. Timely recognition of at-risk patients and careful monitoring can significantly reduce the likelihood of kidney damage.Diagnostic Assessments:The diagnostic process starts with a comprehensive medical history to identify prerenal, intrarenal, and postrenal causes.Prerenal causes, such as dehydration, hypotension, or blood loss, should...
Acute Kidney Injury II: Pathophysiology01:29

Acute Kidney Injury II: Pathophysiology

Acute kidney injury (AKI) causes are categorized into three primary categories based on the location of the injury: prerenal, intrarenal (or intrinsic), and postrenal causes. This classification guides clinical management and illustrates how different pathways can impair kidney function.Etiology and Pathophysiology of Acute Kidney Injury1. Prerenal causesEtiology: Prerenal Acute Kidney Injury, the most common type, occurs when reduced blood flow to the kidneys decreases filtration capacity...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
Acute Kidney Injury I: Introduction01:22

Acute Kidney Injury I: Introduction

Introduction:Acute Kidney Injury (AKI) describes a swift decrease in kidney function occurring over hours to days, characterized by the kidneys' failure to remove waste products from the bloodstream. This leads to dangerous complications like metabolic acidosis, fluid overload, and electrolyte imbalances, such as hyperkalemia, which can cause life-threatening arrhythmias. AKI is common in both hospital and outpatient settings, often triggered by dehydration, sepsis, or exposure to nephrotoxic...